Core Viewpoint - The company, CIMC Enric Holdings Co., Ltd. (中集环科), reported strong financial performance in Q1 2025, with significant growth in new orders and a focus on high-quality development and green initiatives [1][2]. Financial Performance - In Q1 2025, the company achieved revenue of 611 million yuan, net profit attributable to shareholders of 22.38 million yuan, and net cash flow from operating activities of 171 million yuan [1]. - The total new orders signed in the first three months amounted to 444 million yuan, representing a year-on-year increase of 17.27% [1][2]. - As of March 31, 2025, the company had a backlog of orders totaling 791 million yuan [1]. Strategic Initiatives - The company adheres to a development strategy focused on "lean innovation, intelligent transformation, global connectivity, and green development" [1][2]. - In 2024, the company emphasized smart and green development, enhancing its technological research and development, intelligent upgrades, and lean management [1]. - The "flexible green intelligent factory" project was recognized as one of the first batch of excellent intelligent factories by the Ministry of Industry and Information Technology [1]. Green Development Efforts - The company promotes green practices across production, logistics, and process control, including the introduction of solar photovoltaic facilities and the replacement of traditional painting processes with powder coating [2]. - It has been awarded the title of "National Green Factory for 2024" by the Ministry of Industry and Information Technology, reflecting its commitment to reducing environmental impact while enhancing product value [2]. - The focus on green and intelligent development has led to improved product competitiveness and increased recognition among global customers [2].

Core Viewpoint - Company reported a slight decline in overall revenue for Q1 2025, but the medical device components business showed significant growth, indicating a strategic shift towards higher value-added products [1][2]. Group 1: Financial Performance - Company achieved operating revenue of 611.23 million yuan in Q1 2025, a decrease of 1.31% compared to the same period last year [1]. - Revenue from tank containers was 480.76 million yuan, down 2.57% year-on-year [1]. - Medical device components revenue reached 54.41 million yuan, marking a 20.98% increase year-on-year [1]. - Aftermarket business revenue was 36.08 million yuan, with a slight increase of 0.15% year-on-year [1]. Group 2: Business Segment Growth - The medical device components business accounted for 8.90% of total revenue in Q1 2025, up from 7.19% in 2024 [1]. - The company has developed high-end medical imaging equipment components, particularly for MRI machines, gaining recognition from industry leaders [1]. Group 3: Market Trends and Strategic Positioning - The growth in the medical device components business aligns with global trends such as aging populations and increasing health awareness, driving demand for high-end medical equipment [2]. - The Chinese government has initiated policies to enhance medical service levels, which is expected to boost the market for MRI machines and related equipment [2]. - The domestic medical imaging equipment market is projected to grow from 53.7 billion yuan in 2020 to nearly 110 billion yuan by 2030, with a compound annual growth rate of 7.3% [2]. Group 4: Future Outlook - Despite the current low revenue contribution from the medical device components business, its strategic value and performance contribution are expected to increase as the downstream medical imaging market continues to grow [3].

Financial Performance - The company reported a basic earnings per share of 0.0400 yuan for Q1 2025, a decrease of 55.56% compared to 0.0900 yuan in Q1 2024 and a significant drop from 0.4400 yuan in Q1 2023 [1] - The net profit for Q1 2025 was 0.22 billion yuan, down 57.69% from 0.52 billion yuan in Q1 2024 and a sharp decline from 2.23 billion yuan in Q1 2023 [1] - The operating revenue for Q1 2025 was 6.11 billion yuan, a decrease of 1.29% from 6.19 billion yuan in Q1 2024 and a substantial drop from 14.19 billion yuan in Q1 2023 [1] - The return on equity (ROE) for Q1 2025 was 0.47%, down 57.66% from 1.11% in Q1 2024 and a significant decline from 8.46% in Q1 2023 [1] Shareholder Structure - The top ten unrestricted shareholders collectively hold 6.8026 million shares, accounting for 7.56% of the circulating shares, with an increase of 1.9709 million shares compared to the previous period [1] - Notable new shareholders include Ji Zihao with 1.8455 million shares (2.05% of total shares) and Zhi Yuan 38 single asset management plan with 0.3420 million shares (0.38% of total shares) [2] - Hong Kong Central Clearing Limited increased its holdings by 64.18% to 1.4181 million shares (1.58% of total shares) [2] Dividend Policy - The company has decided not to distribute dividends or bonus shares this time [3]

Financial Performance - The company's revenue for Q1 2025 was ¥611,226,370.64, a decrease of 1.31% compared to ¥619,358,847.22 in the same period last year[5] - Net profit attributable to shareholders was ¥22,377,960.10, down 56.99% from ¥52,033,709.00 year-on-year[5] - Basic and diluted earnings per share decreased by 55.56%, from ¥0.09 to ¥0.04[5] - Total operating revenue for the current period was CNY 611,226,370.64, a decrease of 1.83% from CNY 619,358,847.22 in the previous period[19] - Net profit for the current period was CNY 22,024,814.61, down 56.5% from CNY 50,642,603.28 in the previous period[20] Cash Flow and Investments - The net cash flow from operating activities increased by 111.16%, reaching ¥170,778,264.47, compared to ¥80,875,988.23 in the previous year[5] - Operating cash inflow for the current period was $730,450,826.53, an increase from $690,789,911.89 in the previous period, representing a growth of approximately 8.5%[22] - Net cash flow from investment activities was $1,102,276,233.40, a significant improvement from a negative $33,219,921.10 in the prior period[22] - The net increase in cash and cash equivalents for the current period was $1,263,075,715.54, a notable rise from $49,755,356.69 in the previous period[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥5,503,522,621.61, reflecting a 0.93% increase from ¥5,452,806,845.37 at the end of the previous year[5] - Total liabilities increased to CNY 773,330,261.08 from CNY 749,516,475.76, indicating a rise of 3.4%[18] - The total equity attributable to shareholders of the parent company was CNY 4,732,729,228.87, up from CNY 4,705,498,614.70 in the previous period[18] Revenue Segmentation - The revenue from tank containers was CNY 480.76 million, down 2.57% year-on-year, while revenue from medical device components increased by 20.98% to CNY 54.41 million[13] - The company signed new orders totaling CNY 444 million in Q1 2025, representing a growth of 17.27% year-on-year[13] - As of March 31, 2025, the company's backlog of orders was CNY 791 million, a decrease of 17.87% year-on-year[13] Other Financial Metrics - The company reported a significant increase in other comprehensive income, which rose by 1371.23% due to foreign currency translation adjustments[9] - Tax expenses decreased by 62.50% due to a reduction in total profit[9] - The company’s investment income increased by 33.98%, driven by favorable foreign exchange movements[9] - The company’s financial expenses rose by 83.89%, primarily due to increased foreign exchange losses[9] - Research and development expenses were CNY 21,989,054.00, slightly up from CNY 21,387,680.72 in the previous period[19] - The company recorded a fair value gain of CNY 13,054,000.00, compared to a loss of CNY 4,111,700.00 in the previous period[19] - Other comprehensive income after tax for the current period was CNY 2,345,511.48, compared to CNY 336,526.50 in the previous period[20] Market Position and Strategy - The company maintained its market position in the tank container business while experiencing steady growth in the medical device components segment[12] - The company approved the use of self-owned foreign exchange to pay for fundraising projects, allowing for the replacement of equivalent funds from the fundraising account[14] - The company also approved the completion of certain fundraising projects and the permanent allocation of surplus funds to working capital[14] Audit Status - The company’s first quarter report was not audited, indicating a preliminary financial assessment[24]

Group 1: Business Overview - The company primarily engages in the design, manufacturing, and sales of tank containers, achieving a revenue of CNY 334,909.30 million in 2024, with tank container revenue at CNY 274,834.64 million [1] - The company has a total of 2,256 employees as of 2024 [1] - The net profit attributable to the parent company for 2024 was CNY 30,387.02 million [1] Group 2: Market Outlook - The global tank container market had a total of 882,000 units as of January 2025, with a new build volume of 42,100 units in 2024, representing a year-on-year decline of 25.58% [2] - The company anticipates challenges in 2025 due to geopolitical uncertainties and new trade policies affecting global economic recovery [2] Group 3: Order Status - In 2024, the company signed new orders totaling CNY 2,994 million, a decrease of 9.38% year-on-year [2] - As of December 31, 2024, the company had an order backlog of CNY 937 million, down 17.66% compared to the previous year [2] Group 4: Pricing Strategy - Pricing for tank containers is influenced by current market prices of raw materials, customer specifications, and various cost factors including exchange rates [3] Group 5: Competitive Advantages - The company possesses scale, brand, scope, and synergy advantages, enabling effective investment, product upgrades, and cost control [4] - It offers a comprehensive range of tank containers, including standard and special liquid tanks, gas tanks, and powder tanks, across various sizes [4] Group 6: Future Development - The medical equipment components business saw a growth of over 10% last year, and the company plans to increase R&D investment to expand its product range in this sector [5]

北京市金杜律师事务所上海分所 关于中集安瑞环科技股份有限公司 2024 年年度股东会之法律意见书 致：中集安瑞环科技股份有限公司 北京市金杜律师事务所上海分所（以下简称本所）接受中集安瑞环科技股份 有限公司（以下简称公司）委托，根据《中华人民共和国证券法》（以下简称《证 券法》）、《中华人民共和国公司法》（以下简称《公司法》）、中国证券监督管理委 员会《上市公司股东会规则》（以下简称《股东会规则》）等中华人民共和国境内 （以下简称中国境内，为本法律意见书之目的，不包括中国香港特别行政区、中 国澳门特别行政区和中国台湾地区）现行有效的法律、行政法规、规章和规范性 文件和现行有效的《中集安瑞环科技股份有限公司章程》（以下简称《公司章程》） 有关规定，指派律师出席了公司于 2025 年 4 月 14 日召开的 2024 年年度股东 会（以下简称本次股东会），并就本次股东会相关事项出具本法律意见书。 为出具本法律意见书，本所律师审查了公司提供的以下文件，包括但不限于： 1. 经公司 2024 年第二次临时股东大会审议通过的《公司章程》； 2. 公司 2025 年 3 月 22 日刊登于巨潮资讯网及深圳证券交易所（以下 ...

证券代码：301559 证券简称：中集环科 公告编号：2025-013 中集安瑞环科技股份有限公司 2024 年年度股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会未出现否决提案的情形。 2、本次股东会不涉及变更以往股东会已通过决议的情形。 一、会议召开及出席情况 通过深圳证券交易所（以下简称"深交所"）交易系统投票的时间为 2025 年 4 月 14 日 9:15-9:25，9:30-11:30 和 13:00-15:00；通过深交所互联网投票系统 投票的时间为 2025 年 4 月 14 日 9:15-15:00。 2、召开地点：江苏省南通市城港路 159 号中集安瑞环科技股份有限公司 301 会议室 3、召开方式：本次股东会采取现场投票与网络投票相结合的方式。 4、召集人：公司董事会 5、主持人：董事长杨晓虎先生 （一）会议召开情况 1、召开时间： （1）现场会议召开时间：2025 年 4 月 14 日（星期一）下午 14:30 （2）网络投票时间：2025 年 4 月 14 日 3、公司董事、监事、高级管理人员 ...

中信证券股份有限公司 关于中集安瑞环科技股份有限公司 2024年度跟踪报告 | 保荐人名称：中信证券股份有限公司 | 被保荐公司简称： 中集环科 | | --- | --- | | 保荐代表人姓名：施丹 | 联系电话：0755-23835888 | | 保荐代表人姓名：王杰 | 联系电话：021-20262319 | 一、保荐工作概述 | 项目 | 工作内容 | | --- | --- | | 1.公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 无 | | 2．督导公司建立健全并有效执行规章制度的情况 | | | （1）是否督导公司建立健全规章制度（包括但不 限于防止关联方占用公司资源的制度、募集资金 | 是 | | 管理制度、内控制度、内部审计制度、关联交易 | | | 制度） | | | （2）公司是否有效执行相关规章制度 | 是，根据《中集安瑞环科技股份有限公司2024 年度内部控制自我评价报告》《中集安瑞环科 | | | 技股份有限公司内部控制审计报告》，发行人 | | | 有效执行了相关规章制度。 | | 3.募集资金 ...

Group 1 - The company CIMC Enric has been awarded the "Green Intelligent Manufacturing Dual Transformation Benchmark Award" at the 2025 ESG Excellence Award evaluation by the China Top 100 Listed Companies Forum [2] - CIMC Enric was recognized as one of the first "National Excellent Intelligent Factories" by the Ministry of Industry and Information Technology, marking a new paradigm in the digital transformation of the tank container industry [2] - The company implemented digital twin technology in its flexible lighthouse factory project, achieving a 20% increase in production capacity and a 10% reduction in energy consumption [2] Group 2 - CIMC Enric is advancing the "AI + Digital Flaw Detection" technology, which has reached the model training stage, with an accuracy rate of 99% in identifying weld defects [2][3] - The digital flaw detection technology has reduced inspection time from 60-90 minutes to 1-2 minutes, resulting in a 60-fold increase in efficiency and annual cost savings of 1.5 million yuan [3] - The company has developed the first fully automated powder coating line in the tank container industry, achieving near-zero VOC emissions and an annual reduction of 78 tons of emissions [3]

中信证券股份有限公司 关于中集安瑞环科技股份有限公司 2024 年度持续督导定期现场检查报告 保荐人名称:中信证券股份有限公司 被保荐公司简称:中集环科(301559) (以下简称"中信证券"或"保荐人") 保荐代表人姓名:施丹 联系电话:0755-23835888 保荐代表人姓名:王杰 联系电话:021-20205888 现场检查人员姓名:施丹、王杰 现场检查对应期间:2024年度 现场检查时间:2025年3月17日-2025年3月19日 一、现场检查事项 现场检查意见 (一)公司治理 是 ex 不适用 现场检查手段: (1) 查阅了上市公司最新章程、三会议事规则及会议材料; (2)取得上市公司董事、监事、高级管理人员名单及其变化情况; (3)取得上市公司关联方清单; (4) 查阅关于公司控股股东、董事、监事、高级管理人员的信息披露文件及相 关变更决策文件; (5)查看上市公司生产经营场所; (6)对上市公司高级管理人员进行访谈。 1.公司章程和公司治理制度是否完备、合规 是 2.公司章程和三会规则是否得到有效执行 是 3.三会会议记录是否完整,时间、地点、出席人员及会议内 是 容等要件是否齐备,会议资料是 ...